JHL Biotech has developed its own proprietary CHO-K1 cell line and uses this cell line for its own products and those of contract partners. JHL has established process development expertise that allows fine control of protein characteristics. Our robust development platform and scale-up strategies reliably translate from 3L models to GMP manufacturing at 2,000L, reducing the need for time consuming and costly iterations at full scale. JHL has a comprehensive, state-of-the art analytical portfolio applying orthogonal methods and is capable of developing liquid and lyophilized formulations. Both of JHL’s facilities utilize identical single-use manufacturing technologies provided by GE, Millipore, and other leading vendors. Our unified technical platform simplifies process development, manufacturing, and technical transfer. We have experience manufacturing batches for regulatory submission at, 50L, 200L, 500L, and 2,000L scales and have successfully designed and conducted clinical trials of biologics.